Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need
G Pretelli, CC Spagnolo, G Ciappina… - International Journal of …, 2023 - mdpi.com
The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …
Afatinib for the treatment of nsclc with uncommon egfr mutations: A narrative review
Y Jiang, X Fang, Y Xiang, T Fang, J Liu, K Lu - Current Oncology, 2023 - mdpi.com
Afatinib, the world's first irreversible ErbB family (containing four different cancer cell
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …
[HTML][HTML] A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q …
LC Villaruz, X Wang, EM Bertino, L Gu, SJ Antonia… - Esmo Open, 2023 - Elsevier
Background For patients with stage IV non-small-cell lung cancer with epidermal growth
factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib is the …
factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib is the …
SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth
Z Sheng, X Cao, Y Deng, X Zhao, S Liang - Cell Communication and …, 2023 - Springer
Abstract Background The Annexin A6 (AnxA6) protein is known to inhibit the epidermal
growth factor receptor (EGFR)-extracellular signal regulated kinase (ERK) 1/2 signaling …
growth factor receptor (EGFR)-extracellular signal regulated kinase (ERK) 1/2 signaling …
Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with non-small cell lung cancer carrying uncommon EGFR …
HS Li, SZ Wang, HY Xu, X Yan, JY Zhang, SY Lei, T Li… - Cancers, 2022 - mdpi.com
Simple Summary Afatinib has been approved for patients with lung cancer carrying
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
[HTML][HTML] The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
X Man, X Sun, C Chen, Y Xiang, J Zhang… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third
most prevalent mutation in non-small cell lung cancer (NSCLC), following the 19del and …
most prevalent mutation in non-small cell lung cancer (NSCLC), following the 19del and …
Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
Y Lin, L Chen, R Li, X Liu, Q Li, J Cai, Y Du… - Frontiers in …, 2023 - frontiersin.org
Importance Patients with EGFR mutations who have advanced-stage non-small cell lung
cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line …
cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line …
Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
W Li, R Bai, H Guo, J Cui - Chinese Medical Journal, 2023 - mednexus.org
Epidermal growth factor receptor (EGFR) mutations are common oncogenic driver mutations
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Z Du, J Sun, Y Zhang, N Hesilaiti, Q Xia, H Cui, N Fan… - Biomolecules, 2023 - mdpi.com
Oncogenic mutations within the EGFR kinase domain are well-established driver mutations
in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) …
in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) …
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter …
M Sanchis-Borja, F Guisier, A Swalduz… - OncoTargets and …, 2024 - Taylor & Francis
Purpose The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common EGFR …
inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common EGFR …